A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2- Positive Metastatic Breast Cancer With Brain Metastases (BMs) from DESTINY-Breast01, -02, and -03

News
Video

Sara Tolaney, MD, MPH, presents an exploratory pooled analysis of efficacy and safety data of trastuzumab deruxtecan vs comparator in patients with HER2-positive metastatic breast cancer and brain metastases from DESTINY-Breast01, -02, and -03.

Related Videos
Nan Chen, MD
Timothy Yap, MBBS, PhD, FRCP
Parul N Barry, MD,
Erin Frances Cobain, MD
Erin Frances Cobain, MD
Video 6 - "Shared Decision Making and Multidisciplinary Collaboration in the Evolving HR+/HER2- Early-Stage Breast Cancer Landscape"
Manmeet Singh Ahluwalia, MD
Rita Nanda, MD
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Related Content
Samilia Obeng-Gyasi, MD, MPH

Identifying Individual Social Determinants of Health Could Reduce Barriers to Breast Cancer Care

May 14th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Breast Cancer - stock.adobe.com

Fuzuloparib ± Apatinib Significantly Boosts PFS in BRCA+ HER2– Metastatic Breast Cancer

May 9th 2024
Article
Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024
Podcast
Erin Frances Cobain, MD, of the University of Michigan Rogel Cancer Center

Ongoing Research Drives Further Questions in Early-Stage Breast Cancer Management

May 2nd 2024
Article
3d rendered illustration - breast cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

Final USPSTF Recommendation Statement Advises Women Begin Receiving Mammograms at 40 Years Old

May 1st 2024
Article